416 related articles for article (PubMed ID: 28110581)
1. Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.
Boudreault JS; Touzeau C; Moreau P
Expert Rev Hematol; 2017 Mar; 10(3):207-215. PubMed ID: 28110581
[TBL] [Abstract][Full Text] [Related]
2. Treatment of relapsed and refractory multiple myeloma.
Sonneveld P; Broijl A
Haematologica; 2016 Apr; 101(4):396-406. PubMed ID: 27033237
[TBL] [Abstract][Full Text] [Related]
3. Novel agents for multiple myeloma to overcome resistance in phase III clinical trials.
Orlowski RZ
Semin Oncol; 2013 Oct; 40(5):634-51. PubMed ID: 24135408
[TBL] [Abstract][Full Text] [Related]
4. Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.
Nijhof IS; van de Donk NWCJ; Zweegman S; Lokhorst HM
Drugs; 2018 Jan; 78(1):19-37. PubMed ID: 29188449
[TBL] [Abstract][Full Text] [Related]
5. Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat.
Afifi S; Michael A; Azimi M; Rodriguez M; Lendvai N; Landgren O
Pharmacotherapy; 2015 Dec; 35(12):1173-88. PubMed ID: 26684557
[TBL] [Abstract][Full Text] [Related]
6. Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study.
Kaufman JL; Mina R; Jakubowiak AJ; Zimmerman TL; Wolf JJ; Lewis C; Gleason C; Sharp C; Martin T; Heffner LT; Nooka AK; Harvey RD; Lonial S
Blood Cancer J; 2019 Jan; 9(1):3. PubMed ID: 30610196
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action.
Wudhikarn K; Wills B; Lesokhin AM
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101143. PubMed ID: 32139009
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic progress in relapsed/refractory multiple myeloma.
Chen Q; Zhang M; Zheng S; Tong Y; Tan Y
Ann Hematol; 2024 Jun; 103(6):1833-1841. PubMed ID: 38609727
[TBL] [Abstract][Full Text] [Related]
9. Novel therapeutics in multiple myeloma.
Stewart AK
Hematology; 2012 Apr; 17 Suppl 1(0 1):S105-8. PubMed ID: 22507794
[TBL] [Abstract][Full Text] [Related]
10. Future agents and treatment directions in multiple myeloma.
Ocio EM; Mitsiades CS; Orlowski RZ; Anderson KC
Expert Rev Hematol; 2014 Feb; 7(1):127-41. PubMed ID: 24350987
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment.
Morè S; Petrucci MT; Corvatta L; Fazio F; Offidani M; Olivieri A
Pharmaceuticals (Basel); 2020 Nov; 13(12):. PubMed ID: 33260960
[TBL] [Abstract][Full Text] [Related]
12. Progress and Paradigms in Multiple Myeloma.
Anderson KC
Clin Cancer Res; 2016 Nov; 22(22):5419-5427. PubMed ID: 28151709
[TBL] [Abstract][Full Text] [Related]
13. Emerging drugs and combinations to treat multiple myeloma.
Larocca A; Mina R; Gay F; Bringhen S; Boccadoro M
Oncotarget; 2017 Sep; 8(36):60656-60672. PubMed ID: 28948001
[TBL] [Abstract][Full Text] [Related]
14. Emerging agents and regimens for multiple myeloma.
Yang Y; Li Y; Gu H; Dong M; Cai Z
J Hematol Oncol; 2020 Nov; 13(1):150. PubMed ID: 33168044
[TBL] [Abstract][Full Text] [Related]
15. Development of target-specific treatments in multiple myeloma.
Chanan-Khan AA; Borrello I; Lee KP; Reece DE
Br J Haematol; 2010 Oct; 151(1):3-15. PubMed ID: 20618339
[TBL] [Abstract][Full Text] [Related]
16. Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor.
Redic KA; Hough SM; Price EM
Onco Targets Ther; 2016; 9():2783-93. PubMed ID: 27274274
[TBL] [Abstract][Full Text] [Related]
17. New investigational drugs with single-agent activity in multiple myeloma.
Rajan AM; Kumar S
Blood Cancer J; 2016 Jul; 6(7):e451. PubMed ID: 27471867
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Panobinostat for the Treatment of Multiple Myeloma.
Eleutherakis-Papaiakovou E; Kanellias N; Kastritis E; Gavriatopoulou M; Terpos E; Dimopoulos MA
J Oncol; 2020; 2020():7131802. PubMed ID: 32411240
[TBL] [Abstract][Full Text] [Related]
19. The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies.
Hernández-Rivas JÁ; Ríos-Tamayo R; Encinas C; Alonso R; Lahuerta JJ
Biomark Res; 2022 Jan; 10(1):1. PubMed ID: 35000618
[TBL] [Abstract][Full Text] [Related]
20. Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Kumar SK; Callander NS; Adekola K; Anderson LD; Baljevic M; Baz R; Campagnaro E; Castillo JJ; Costello C; D'Angelo C; Devarakonda S; Elsedawy N; Garfall A; Godby K; Hillengass J; Holmberg L; Htut M; Huff CA; Hultcrantz M; Kang Y; Larson S; Lee HC; Liedtke M; Martin T; Omel J; Robinson T; Rosenberg A; Sborov D; Schroeder MA; Sherbenou D; Suvannasankha A; Valent J; Varshavsky-Yanovsky AN; Kumar R; Snedeker J
J Natl Compr Canc Netw; 2023 Dec; 21(12):1281-1301. PubMed ID: 38081133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
